Hexarelin
PeptideThe medical score is 24 points below the community score: clinical studies are small and limited to GH surrogate markers [s4, s5], whereas community reports primarily assess subjective performance and body composition effects that are not supported by RCTs [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Hexarelin is the most potent GHRP available, driving stronger GH release than ipamorelin or GHRP-6 — but at the cost of notable cortisol and prolactin elevation and rapid receptor desensitization within 4–6 weeks. Cardioprotective effects are well-documented in animals but unproven in humans. No regulatory approval, WADA-banned, legally ambiguous — not a beginner compound. Anyone prone to cortisol or prolactin issues should default to ipamorelin instead.
Description
Hexarelin is a synthetic hexapeptide GHS that stimulates growth hormone release via GHS-R1a and CD36 and exhibits cardioprotective effects. No FDA/EMA approval [s1, s4].
Hexarelin (Examorelin) is a synthetic hexapeptide of the growth hormone secretagogue (GHS) class, developed in the 1990s as an analogue of GHRP-6 [s2]. It binds with high affinity to the ghrelin receptor GHS-R1a, expressed in both the hypothalamus and the pituitary gland, and stimulates growth hormone (GH) secretion from somatotroph cells [s1, s3]. Hexarelin is considered the most potent of all GHRP peptides with respect to acute GH release in humans; however, compared to more selective GHRPs such as Ipamorelin, it exhibits more pronounced off-target effects, particularly elevated cortisol and prolactin secretion, as well as rapid receptor desensitization (tachyphylaxis) after 4–8 weeks of continuous use [s5, s6, s7]. In addition, Hexarelin possesses cardioprotective properties mediated independently of the GH axis via the CD36 receptor on cardiac muscle. Animal studies demonstrate a reduction in infarct size, decreased cardiac fibrosis, and improved ventricular function following myocardial infarction [s8, s9, s10]. In humans, there is evidence of improved left ventricular ejection fraction (LVEF) in hypopituitary adults following acute intravenous Hexarelin administration; however, controlled clinical studies on cardioprotection are currently lacking [s4]. Peak GH levels correlate negatively with body fat percentage, BMI, and body weight — obese individuals exhibit a reduced GH response to Hexarelin [s11]. In animal models, Hexarelin improved body composition in insulin-resistant mice by reducing fat mass and increasing muscle mass [s15]. Hexarelin is approved by neither the FDA nor the EMA for human use and is listed on the WADA prohibited list [s12, s13].
Legal Status (DE)
Hexarelin is neither approved as a medicinal product nor marketable as a dietary supplement in Germany, Austria, or Switzerland. It is classified as an unapproved research chemical pursuant to AMG §2. Possession by private individuals is legally ambiguous; distribution for human use is illegal without marketing authorization. Hexarelin is also listed on the WADA prohibited list [S2] and is banned in sport worldwide [s12, s13].
Mechanism of Action
Hexarelin exerts its effects via two primary receptor pathways: 1. GHS-R1a (ghrelin receptor): Hexarelin binds with high affinity to GHS-R1a in the hypothalamus and anterior pituitary. This binding activates the phospholipase C (PLC) signaling cascade, leading to an increase in intracellular calcium concentration in somatotroph cells and stimulating pulsatile GH secretion [s1, s3]. Hexarelin acts as an orthosteric super-agonist at GHS-R1a and activates the G-protein pathway Gαo1 [s3]. GH release is dose-dependent and is synergistically enhanced by endogenous GHRH [s4]. 2. CD36 receptor (scavenger receptor class B): Independently of the GH axis, Hexarelin binds to the cardiac CD36 receptor and mediates direct cardioprotective effects. Via this pathway, inflammatory processes are inhibited, fibrosis formation is reduced, and myocardial function is improved following ischemic events [s8, s9, s10]. Additionally, at higher doses Hexarelin stimulates the release of prolactin and ACTH/cortisol via hypothalamic and pituitary pathways, which is considered an undesirable side effect [s6, s7]. With chronic use, rapid desensitization of GHS-R1a occurs, leading to a marked attenuation of the GH response (tachyphylaxis) [s5, s7].
Dosing
GH-Stimulation (akut, Forschung)
- Dose
- 100 mcg per injection
- Frequency
- 1–3× täglich subkutan
- Route
- injektion-subkutan
- Duration
- 4–6 Wochen (dann Pause empfohlen)
- Timing
- Fasted, in the morning and/or before bedtime
- With food
- vermeiden
GH-Stimulation (klinische Forschungsdosis, intravenös)
- Dose
- 2 mcg/kg body weight i.v.
- Frequency
- Einmalgabe (Bolus)
- Route
- oral
- Duration
- Einmalanwendung (Studienprotokoll)
- Timing
- Under medical supervision only
- With food
- vermeiden
Körperzusammensetzung / Langzeitprotokoll
- Dose
- 1.5 mcg/kg body weight s.c.
- Frequency
- 2× täglich subkutan
- Route
- injektion-subkutan
- Duration
- Maximal 16 Wochen, danach mindestens 4 Wochen Pause
- Timing
- Fasted (at least 30 min before a meal)
- With food
- vermeiden
In clinical studies, intravenous bolus doses of 2 mcg/kg BW were used as the upper research limit [s14]. Subcutaneously administered long-term doses were 1.5 mcg/kg twice daily [s5]. Higher doses markedly increase cortisol/prolactin side effects [s6, s7]. No officially recommended maximum clinical dose exists, as no approval has been granted.
Hexarelin should not be used daily for more than 4–8 weeks, as pronounced receptor desensitization will otherwise occur [s5, s7]. Food intake prior to injection reduces GH release [s4]. Oral and nasal administration show significantly lower bioavailability than subcutaneous injection [s14].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Hypoglykämie | selten | leicht |
Contraindications
GH secretagogues can stimulate the IGF-1 system, which exerts proliferative effects in certain tumor entities. Hexarelin is contraindicated in known malignancies [s5].
As hexarelin increases prolactin secretion, it is contraindicated in pre-existing hyperprolactinemia or prolactinoma [s6, s7].
No human safety data available. Use contraindicated [s5].
GH elevations can increase insulin resistance and destabilize blood glucose [s5].
Growth hormone stimulation during the growth phase carries the risk of acromegaly or uncontrolled growth promotion [s5].
Hexarelin (examorelin) is listed on the WADA Prohibited List S2 and is fully prohibited during competition and training periods [s12, s13].
Interactions
Synergistic
Hexarelin and Ipamorelin both stimulate the growth hormone secretagogue receptor (GHS-R1a), promoting GH release from the pituitary; the combination may lead to enhanced GH release through additive receptor agonism and differing binding kinetics.
Hexarelin activates the GHS-R1a receptor (GHRP mechanism), while CJC-1295 without DAC, as a short-acting GHRH analogue, stimulates the GHRH receptor; simultaneous activation of both receptor pathways acts synergistically on pituitary GH secretion.
Hexarelin (GHS-R1a agonist) and CJC-1295 with DAC (long-acting GHRH analogue with Drug Affinity Complex) stimulate complementary GH secretion signaling pathways, with CJC-1295 DAC achieving prolonged GHRH activity via albumin binding, thereby potentiating pulsatile GH release by Hexarelin.
Hexarelin enhances systemic GH release via GHS-R1a, while BPC-157 mediates local cytoprotective and regenerative effects through NO synthase modulation and growth factor upregulation (including VEGF, EGF); the combination may support anabolic and tissue-regenerative processes via complementary pathways.
Hexarelin promotes systemic GH release and thereby anabolic processes, while TB-500 (Thymosin β4) promotes tissue regeneration through actin sequestration and upregulation of cell migration and angiogenesis pathways; both substances act synergistically on healing and regenerative processes via distinct mechanisms.
Hexarelin and GHRP-2 both stimulate the GHS-R1a receptor and together can produce a significantly greater GH release. Hexarelin is considered more potent than GHRP-2. However, combining both GHRPs is uncommon and increases the risk of desensitization.
Hexarelin is the more potent GHRP compared to GHRP-6 and can generate a significantly higher GH amplitude. Concurrent use of both GHRPs is rarely practical but may further increase GH release.
The combination of Hexarelin (GHS-R1a agonist) and CJC-1295 No DAC (GHRH-R agonist) produces synergistically enhanced GH release through complementary receptor pathways. Together they can trigger 2–3-fold higher GH pulses than either peptide alone. This is one of the most commonly described GHRP/GHRH combinations.
Hexarelin enhances the systemic GH/IGF-1 axis, while TB-500 promotes tissue regeneration locally and systemically. This combination is described for accelerated recovery from tendon, joint, and muscle injuries.
Caution
Hexarelin is the most potent GHRP and leads to faster receptor desensitization (GHS-R1a downregulation) with prolonged use than other GHRPs such as Ipamorelin. Cycles should therefore be kept shorter. Continuous use without breaks is not recommended.
Concurrent use of Hexarelin and GHRP-2 is not advisable due to overlapping GHS-R1a activation and increased risk of elevated prolactin/cortisol. Both peptides raise prolactin and cortisol more than Ipamorelin; combining them potentiates these side effects.
Studies
Tier A — High Evidence
Community Evidence
Top reported benefits
- Enhanced GH effect and muscle growth (especially in combination with CJC-1295)
- Improved post-training recovery time
- Increased endurance in the gym
- Potential cardiovascular health effects (community-discussed)
Top reported issues
- Marked appetite increase (less than GHRP-6, but noticeable)
- Rapid desensitization after 4–6 weeks
- Noticeable cortisol and prolactin effects (mood swings, libido changes)
- Lower availability and higher cost than ipamorelin
Community users frequently report the necessity of cycling (on/off) due to rapid loss of efficacy. Several users switch to Ipamorelin following negative experiences with cortisol/prolactin effects. Evidence for cardioprotective effects in humans is discussed within the community, but is typically extrapolated uncritically from animal studies [c1, c2, c3].
Scientific Sources
- What Is Hexarelin Peptide? (Growth Hormone Secretagogue) – Mechanism and Receptor Binding
Real Peptides Editorial Team (2024). RealPeptides.co (commercial review)CLink - One dose of oral hexarelin protects chronic cardiac function after myocardial infarction
Xu X, Jiang H, Li H, et al. (2014). PeptidesCPMID:24747279DOI - The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects
Rahim A, O'Neill PA, Shalet SM (1998). Clinical EndocrinologyBPMID:10197083DOI - 2025 Prohibited List – World Anti-Doping Agency
World Anti-Doping Agency (2024). WADAALink - Are Peptides Legal? Complete 2026 Status by Country
Guide to Peptide Editorial Team (2026). GuideToPeptide.com (regulatory overview)CLink - Effects of recombinant human insulin-like growth factor I administration on growth hormone secretion stimulated by GHRH or hexarelin in humans
Cordido F, Peino R, Penalva A, et al. (1999). Journal of Clinical Endocrinology & MetabolismAPMID:9920097DOI - Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice
Zhao LP, Cai BZ, Dong J, et al. (2017). EndocrinologyCDOI - Peptide in Deutschland & EU: Rechtslage, Zulassung & Strafbarkeit
Elmntlab.de Editorial Team (2025). Elmntlab.deCLink - Cardiac effects of hexarelin in hypopituitary adults
Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Boghen MF, Ghigo E (1999). European Journal of PharmacologyCDOI - Hexarelin Peptide | Mechanism, GH Release, Safety
Peptide Dose Calculator Editorial Team (2024). PeptideDoseCalculator.com (commercial review)CLink - Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor
Bennett KA, Langmead CJ, Wise A, et al. (2009). Molecular PharmacologyCPMID:19671705DOI - The cardiovascular action of hexarelin
Bisi G, Podio V, Valetto MR, et al. (2014). Journal of Translational Medicine / PMCBDOI - Growth Hormone Status during Long-Term Hexarelin Therapy
Leal-Cerro A, Torres E, Astorga R, et al. (1998). Journal of Clinical Endocrinology & MetabolismBPMID:9589661DOI - The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin
Leal-Cerro A, Garcia-Luna PP, Astorga R, et al. (1999). Clinical Endocrinology (PubMed)BPMID:10341859 - Hexarelin Guide: Benefits, Dosage, Side Effects & Research
WolveStack Editorial Team (2025). WolveStack.com (commercial review)CLink - Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction
Cai BZ, Zhao LP, Dong J, et al. (2018). PMC / Cardiovascular ResearchCLink - Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion
Choubey M, Ranjan AK, Bhatt DL, et al. (2020). Biomedicine & PharmacotherapyCDOI
Community Sources
Storage
Unopened
Lyophilized powder: store at -20 °C, protected from light and moisture. Shelf life unopened up to 24 months.
Opened
After reconstitution with bacteriostatic water: store at 2–8 °C (refrigerator). Use within 28 days.
Notes
Avoid repeated freeze-thaw cycles, as these damage the peptide structure. Do not shake the reconstituted solution.